Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction.
CONCLUSION: The treatment of HFrEF patients with sacubitril/valsartan versus enalapril is cost effective, if a willingness-to-pay threshold of CHF 50 000 per QALY gained ratio is assumed.
PMID: 29185253 [PubMed - in process]
Source: Swiss Medical Weekly - Category: General Medicine Authors: Ademi Z, Pfeil AM, Hancock E, Trueman D, Haroun RH, Deschaseaux C, Schwenkglenks M Tags: Swiss Med Wkly Source Type: research
More News: Cardiology | Diovan | Enalapril | General Medicine | Health Management | Heart | Heart Failure | Switzerland Health